AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0
slide-1
slide-2

Glytas M 30mg/500mg Tablet ER

Prescription Icon
Prescription Required

Marketer

Tas Med India Pvt Ltd

Salt Composition

Gliclazide (30mg) + Metformin (500mg)

Overview Glytas M 30mg/500mg Tablet ER

Diabetic patients may benefit from the extended-release Glytas M 30mg/500mg tablet, a dual-action antidiabetic medication. This combination therapy, for adult type 2 diabetes management, effectively regulates blood glucose. Administer this medication with food, consistently at the same time daily for optimal efficacy. Dosage is determined by your physician and may adjust based on blood sugar monitoring. Continuous use is crucial; discontinuation without medical consultation risks elevated blood sugar, potentially leading to kidney complications, vision impairment, neuropathy, and limb loss. Remember, this medication complements a comprehensive diabetes management plan, including diet, exercise, and weight management as advised by your healthcare provider. Lifestyle choices significantly impact diabetes control. Common side effects include hypoglycemia (low blood sugar), characterized by sweating, dizziness, headache, and tremors, alongside constipation and vomiting. Regular meals and readily available glucose sources (e.g., sugary foods, fruit juice) are essential to mitigate hypoglycemia. Alcohol consumption should be minimized due to its potential to exacerbate low blood sugar. Additional possible side effects encompass altered taste, nausea, diarrhea, abdominal discomfort, cephalgia, and upper respiratory infections. Weight gain may occur. This medication is contraindicated for type 1 diabetes, diabetic ketoacidosis, or severe hepatic or renal impairment. Prior heart conditions should be disclosed to your physician before initiating treatment. Pregnant or lactating individuals require medical consultation before use. Regular blood glucose monitoring is necessary, along with potential blood tests to assess blood cell counts and liver function.

Uses of Glytas M 30mg/500mg Tablet ER

Adult-onset diabetes

Major Benefits of Glytas M 30mg/500mg Tablet ER:

Administer this medication precisely as prescribed by your physician, adhering to both dosage and treatment length. Ingest the Glytas M 30mg/500mg Extended-Release tablet whole; avoid chewing, crushing, or fracturing. Consume this medication with food.

Common Side effects of Glytas M 30mg/500mg Tablet ER:

  • Hypoglycemia (low blood glucose level)
  • Headache
  • Dizziness
  • Diarrhea
  • Upper respiratory tract infection
  • Nausea
  • Flatulence
  • Constipation

How to use Glytas M 30mg/500mg Tablet ER:

Follow your doctor's instructions precisely regarding dosage and treatment length for Glytas M 30mg/500mg Extended-Release Tablets. Ingest the tablets whole; do not damage them by chewing, crushing, or breaking. Consume this medication with food.

How Glytas M 30mg/500mg Tablet ER works:

Glytas M extended-release tablets (30mg/500mg) contain gliclazide and metformin, two medications used to manage blood sugar levels.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Concurrent alcohol use with Glytas M 30mg/500mg extended-release tablets is contraindicated.

PregnancyPregnancyCONSULT YOUR DOCTOR

Extended-release Glytas M 30mg/500mg tablets pose a confirmed risk to a fetus and should not be used during pregnancy. In exceptional, life-threatening circumstances, a physician might prescribe it if the potential benefits outweigh the known dangers. Always seek medical advice.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Extended-release Glytas M 30mg/500mg tablets are likely not safe for use while breastfeeding. Available human data indicate potential drug transfer to breast milk, posing a risk to the infant.

DrivingDrivingCAUTION

Driving may be impaired if your blood glucose levels are outside the normal range. Refrain from driving if such symptoms arise.

KidneyKidneyCAUTION

Patients with kidney impairment should use Glytas M 30mg/500mg Extended-Release tablets cautiously, potentially requiring dosage modification. Severe kidney disease contraindicates the use of Glytas M 30mg/500mg Extended-Release tablets. Physician consultation is recommended. Regular kidney function monitoring is advised during treatment.

LiverLiverCAUTION

Patients with liver impairment should use Glytas M 30mg/500mg Extended-Release Tablets cautiously, potentially requiring dosage modification. Medical advice is necessary. For those with mild to moderate liver disease, Glytas M 30mg/500mg Extended-Release Tablets are typically initiated at a low dose; however, it's contraindicated in individuals with severe hepatic dysfunction.

What if you forget to take Glytas M 30mg/500mg Tablet ER :

Should you forget to take a Glytas M 30mg/500mg Extended-Release Tablet, administer it immediately upon recollection. However, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Glytas M 30mg/500mg Tablet ER

LabelValue
Developing Habits No.
Treatment Category Diabetes Management

FAQs on Glytas M 30mg/500mg Tablet ER

Glytas M 30mg/500mg Extended-Release tablets combine gliclazide and metformin to manage type 2 diabetes mellitus in adults. This combination improves blood sugar control when used with a healthy diet and exercise. Gliclazide stimulates insulin release from the pancreas, while metformin reduces liver glucose production and enhances insulin sensitivity. This medication is not suitable for type 1 diabetes.
Glytas M 30mg/500mg Tablet ER may cause common side effects such as hypoglycemia, altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infection. Rare but serious side effects include lactic acidosis. Prolonged use can also result in vitamin B12 deficiency.
Glytas M 30mg/500mg Tablet ER can cause low blood sugar (hypoglycemia), manifesting as nausea, headache, irritability, hunger, sweating, dizziness, rapid heart rate, anxiety, or shakiness. This risk increases with missed meals, alcohol consumption, excessive exercise, or concurrent use of other diabetes medications. Regular blood sugar monitoring is crucial. Carry glucose tablets, honey, or fruit juice for emergencies.
Glytas M 30mg/500mg Tablet ER can cause lactic acidosis, a serious medical emergency characterized by excessive blood lactic acid (also known as MALA, or Metformin-associated lactic acidosis). This rare side effect is less likely in patients without kidney disease, those who are younger, and those who don't consume large amounts of alcohol. Symptoms may include muscle pain or weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience these, discontinue Glytas M 30mg/500mg Tablet ER and seek immediate medical attention.
Long-term use of Glytas M 30mg/500mg Tablet ER can lead to vitamin B12 deficiency by interfering with its stomach absorption. This deficiency, if left untreated, may result in anemia, nerve damage (manifested as tingling, numbness in extremities, weakness, and ataxia), urinary issues, and cognitive changes. To mitigate this risk, supplemental vitamin B12 is recommended at least annually by some researchers.
Glytas M 30mg/500mg Tablet ER is contraindicated in patients with allergies to its components or excipients, and in those with moderate to severe kidney disease or metabolic acidosis (including diabetic ketoacidosis).
Combining Glytas M 30mg/500mg ER tablets and alcohol is unsafe. Alcohol can worsen low blood sugar and raise the risk of lactic acidosis.
Glytas M 30mg/500mg Extended-Release tablets combine gliclazide and metformin to manage type 2 diabetes mellitus in adults. This combination improves blood sugar control when used with diet and exercise. Gliclazide stimulates insulin release from the pancreas, while metformin reduces liver glucose production and enhances insulin sensitivity. It is not suitable for type 1 diabetes.
Glytas M 30mg/500mg ER tablets may cause common side effects such as low blood sugar (hypoglycemia), altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects, including lactic acidosis, are also possible. Prolonged use may result in vitamin B12 deficiency.
Glytas M 30mg/500mg ER tablets can cause low blood sugar (hypoglycemia), characterized by nausea, headache, irritability, hunger, sweating, dizziness, rapid heartbeat, anxiety, or shakiness. This risk increases if meals are missed or delayed, alcohol is consumed, excessive exercise occurs, or other diabetes medications are used concurrently. Therefore, regular blood sugar monitoring is crucial. Always carry glucose tablets, honey, or fruit juice.
Glytas M 30mg/500mg Tablet ER can cause lactic acidosis, a serious medical emergency characterized by excessive blood lactic acid (also known as MALA, or Metformin-associated lactic acidosis). This rare side effect is preventable by avoiding use in patients with kidney disease, the elderly, or those who consume excessive alcohol. Symptoms include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience these, discontinue Glytas M 30mg/500mg Tablet ER and seek immediate medical attention.
Prolonged use of Glytas M 30mg/500mg Tablet ER can lead to vitamin B12 deficiency by impairing its absorption in the stomach. This deficiency, if left untreated, may result in anemia, neurological issues such as tingling, numbness in extremities, weakness, urinary problems, cognitive changes, and ataxia. To mitigate this risk, supplemental vitamin B12 intake, at least annually, is recommended by some researchers.
Glytas M 30mg/500mg Tablet ER is contraindicated in patients with known allergies to its components or excipients, and in those with moderate to severe kidney disease or metabolic acidosis (including diabetic ketoacidosis).
Combining Glytas M 30mg/500mg ER tablets and alcohol is unsafe. This combination can cause dangerously low blood sugar (hypoglycemia) and raise the risk of lactic acidosis.
Glytas M 30mg/500mg Table...
94
MRP 115
18% off